ClinicalTrials.gg
RecruitingNCT03748069PIASUpdated Nov 17, 2025

Influenza Associated Aspergillosis In-depth Investigation

An observational study in Influenza With Pneumonia and Invasive Pulmonary Aspergillosis, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU.

Read the detailed description

This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU, and correlate findings with occurrence of secondary invasive pulmonary aspergillosis infection.

All consecutive patients aged 18 or older admitted to ICU during the inclusion period with respiratory distress due to influenza positive/negative community acquired pneumonia (CAP) will be included.

02

Conditions studied

  • Influenza With Pneumonia
  • Invasive Pulmonary Aspergillosis

Keywords

  • Influenza
  • IPA
  • ICU
  • Immunology
03

In context

Invasive Pulmonary Aspergillosis

43 studies on the registry are indexed under Invasive Pulmonary Aspergillosis; 9 are open to participants now.

This study's planned enrollment of 45 is below the median of 130 across 27 observational studies indexed under Invasive Pulmonary Aspergillosis.

Browse Invasive Pulmonary Aspergillosis studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically ill community-acquired pneumonia patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients older than 18 years, admitted to ICU with respiratory distress with microbiologically confirmed diagnosis of influenza (for inclusion in the influenza group)
  • All patients older than 18 years, admitted to ICU for respiratory distress due to community- acquired pneumonia , with a microbiologically confirmed absence of influenza (for inclusion in the control group)

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years old
  • Pregnant women
  • No
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Influenza positive CAPIV

    All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza

  • Influenza negative CAPIV

    All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza

06

What researchers measure

Primary outcomes

  1. Difference in immune cell profile in blood between influenza and non-influenza CAPIV patients at ICU.

    Immunophenotyping of blood will be performed to determine number of neutrophils, T- and B-cell subsets, NK cell and myeloid cell subsets. Difference in influenza positive and influenza negative patients is expected.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  2. Difference in cytokine production of mononuclear cells to fungal stimulation in blood between influenza and non-influenza CAPIV patients at ICU.

    Key cytokine reaction of mononuclear cells (PBMC) after fungal stimulation will be performed. Difference in influenza positive and influenza negative patients is expected.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  3. Difference in function of blood neutrophils between influenza and non-influenza CAPIV patients at ICU.

    Functional analysis by killing assay will be performed.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  4. Difference in in immune cell profile in BAL fluid between influenza and non-influenza CAPIV patients at ICU.

    Immunophenotyping of BAL fluid will be performed to determine number of neutrophils, T- and B-cell subsets, NK cell and myeloid cell subsets. Difference in influenza positive and influenza negative patients is expected.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  5. Difference in cytokine production of mononuclear cells to fungal stimulation in BAL fluid between influenza and non-influenza CAPIV patients at ICU.

    Key cytokine reaction of mononuclear BAL fluid cells after fungal stimulation will be performed. Difference in influenza positive and influenza negative patients is expected.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  6. Difference in function of BAL fluid neutrophils between influenza and non-influenza CAPIV patients at ICU.

    Functional analysis by killing assay will be performed.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  7. Difference in pathological hallmarks between influenza and non-influenza CAPIV patients at ICU.

    Biopsies of respiratory tract tissue will be compared between two groups.

    Time frame: through study completion, after 3 influenza seasons (3 years)

Secondary outcomes

  1. Difference in longitudinal alterations in phagocytic cell and mononuclear inflammatory cell subsets in blood and BAL fluid and their response to fungal stimulation between the main study arms.

    Longitudinal alterations in advanced immunophenotyping results and (fungal) cell stimulation will be analysed and compared between groups.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  2. Longitudinal differences in anatomopathological characteristics of the respiratory tract in CAPIV +/- influenza

    Respiratory tract biopsies will be compared longitudinally throughout the disease course.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  3. Correlation of findings with invasive pulmonary aspergillosis incidence

    All data will be compared within each group between patients that develop IPA vs no development of IPA.

    Time frame: through study completion, after 3 influenza seasons (3 years)

  4. Correlation of findings with outcome

    All data will be compared to outcome measures (length of ICU stay, mortality, etc) to find hallmarks of severe disease.

    Time frame: through study completion, after 3 influenza seasons (3 years)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for Apr 2027, 99 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2018
First posted
Nov 20, 2018
StartActual
Jan 18, 2019
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03748069
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Jan 18, 2019
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Joost Wauters, PhD
Contact
joost.wauters@uzleuven.be
16344275 ext. +32
Lore Vanderbeke, MD
Contact
lore.vanderbeke@uzleuven.be
16344275 ext. +32
Joost Wauters, PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion